Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in COVID-19 pneumonia
NCT04393051Phase 2Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib in COVID-19 pneumonia (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Need of invasive mechanical ventilation at 14 days. Status: unknown.
02
Drugs
baricitinib
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04393051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393051.